Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants

ČEŠKOVÁ, Eva. Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants. EXPERT OPINION ON PHARMACOTHERAPY. Abingdon: TAYLOR & FRANCIS LTD, 2016, vol. 17, No 14, p. 1835-1837. ISSN 1465-6566. Available from: https://dx.doi.org/10.1080/14656566.2016.1219340.

Basic information

• Original name: Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants
• Authors: ČEŠKOVÁ, Eva.
• Edition: EXPERT OPINION ON PHARMACOTHERAPY, Abingdon, TAYLOR & FRANCIS LTD, 2016, 1465-6566.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30104 Pharmacology and pharmacy
• Country of publisher: United Kingdom of Great Britain and Northern Ireland
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 3.894
• Organization unit: Central European Institute of Technology
• Doi: http://dx.doi.org/10.1080/14656566.2016.1219340
• UT WoS: 000384401200001
• Keywords in English: Depressive disorder; pharmacoresistance; multimodal; multifunctional antidepressants; pharmacogenomic tests
• Tags: EDITORIAL

Abstract

Major depressive disorder (MDD) is a widespread disease, with a lifetime prevalence of 15% and an annual incidence of approximately 7%. It is associated with significant costs in quality of life, loss of work productivity, and a high risk of mortality. It is predicted to become the leading cause of disability in Western countries by 2030.

Links

• LQ1601, research and development project: Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR